DDW2014: Coverage of Digestive Disease Week 2014
- Details
- Category: HBV Treatment
- Published on Saturday, 31 May 2014 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2014 Digestive Disease Week annual meeting (DDW 2014) in Chicago, May 3-6, 2014.
Hepatitis C
New Hepatitis C Treatments Highlighted at Digestive Disease Week
Some Negative Predictive Factors Do Not Impair Response to Faldaprevir
AbbVie Interferon-free Regimen Cures More than 90% of Hepatitis C Patients
Sustained Response to Interferon Is Durable in Children with Hepatitis C
HIV/HCV Coinfection
Some Negative Predictive Factors Do Not Impair Response to Faldaprevir
Hepatitis B
Outcomes in HBV/HCV Coinfected People Depend on Which Virus Dominates
Some Hepatitis B Patients Can Stop Antiviral Treatment Without Relapse
Complications and Related Conditions
Rifaximin May Be Beneficial for People with Advanced Liver Cirrhosis
Drinking More Coffee Is Associated with Less Liver Fibrosis
DDW 2013: Does HBV Suppression Prevent Liver Disease Progression?
- Details
- Category: HBV Treatment
- Published on Wednesday, 19 June 2013 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients with cirrhosis may still experience liver disease progression even if they undergo antiviral treatment and achieve good virological response, according to a poster presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando.
DDW 2013: Tenofovir and Entecavir Effectively Suppress Hepatitis B Virus
- Details
- Category: HBV Treatment
- Published on Thursday, 06 June 2013 00:00
- Written by Liz Highleyman
The newer antivirals tenofovir (Viread) and entecavir (Baraclude) inhibit hepatitis B virus (HBV) replication more effectively than older agents, but good adherence is needed to maintain long-term viral suppression, according to a set of studies presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando.
DDW 2013: Prior Non-responders Can Achieve Good SVR Rates with Boceprevir Triple Therapy
- Details
- Category: HCV Treatment
- Published on Thursday, 06 June 2013 00:00
- Written by Liz Highleyman
People previously treated with interferon-based therapy can achieve good results when retreated with boceprevir (Victrelis) triple therapy, according to final results from the PROVIDE study presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando. Prior relapsers had the best response, but even 41% of prior null responders achieved a cure.
DDW 2013: Drug Interactions May Compromise Response to Boceprevir and Telaprevir
- Details
- Category: HCV Treatment
- Published on Thursday, 30 May 2013 00:00
- Written by Liz Highleyman
Concurrent use of drugs that alter concentrations of boceprevir (Victrelis) or telaprevir (Incivek or Incivo) in the body may contribute to poor response to interferon-based triple therapy for chronic hepatitis C, according to study findings presented at the Digestive Disease Week meeting (DDW 2013) last week in Orlando.
More Articles...
- DDW 2013: Interferon-free Simeprevir + Sofosbuvir Suppresses Hepatitis C with or without Ribavirin
- DDW 2013: Advanced Fibrosis Does Not Affect Response to Faldaprevir All-oral Regimen
- DDW 2013: Viral Breakthrough May Occur during Interferon/Ribavirin 'Tail' of HCV Triple Therapy
- DDW 2013: Does Treating Herpes Help Suppress Hepatitis C Virus?
Web Design and Development by